文献速递药物相互作用治疗药物监测与药物基因组学

基于微剂量咪达唑仑持续输注群体药动学模型量化CYP3A抑制、激活与诱导的时间过程

Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
PubMed 文献 · Clin Pharmacokinet · 2022-10-04

结果可依据起效时间区分不同调节机制,各 perpetrator 的最大清除率相对变化分别为依非韦伦+59.1%、利福平+46.7%、口服伏立康唑-70.6%、静脉伏立康唑-61.1%。

要点

  • 依非韦伦激活起效快而短,约2–3 h达最大效应。
  • 利福平诱导延迟出现,约22 h后可观察到,28–30 h达峰后1–2 h内陡降至近基线。
  • 口服与静脉伏立康唑抑制持久且逐渐增强,至8 h采样结束仍在上升。

核心结论

  • 可依据起效时间区分CYP3A不同调节机制,各 perpetrator 的最大清除率相对变化为依非韦伦+59.1%、利福平+46.7%、口服伏立康唑-70.6%、静脉伏立康唑-61.1%。
  • 识别每种 perpetrator 使清除率显著变化的时间点,可指导未来药物相互作用研究的最佳采样方案设计。
  • 短期联合不同 perpetrator 对咪达唑仑的影响已表征,可界定预期无相关相互作用的联合间隔。

研究设计与样本

  • perpetrator 包括伏立康唑(口服或静脉)、利福平(口服)、依非韦伦(口服)。
  • 咪达唑仑 bolus 后,利福平组每小时采血,其余组每15 min采血至输注结束;共1858个浓度在咪达唑仑与1'-羟基咪达唑仑间均分。
  • 使用NONMEM®建立两化合物的非线性混合效应群体药动学模型,以相对安慰剂组清除率变化量化CYP3A活性调节。

主要发现

  • 依非韦伦CYP3A激活相对快速且短暂,约2–3 h达最大效应。
  • 利福平诱导效应约22 h后才可观察到,约28–30 h达最大,随后1–2 h内陡降至近基线。
  • 口服与静脉伏立康唑的抑制影响持久,CYP3A活性持续抑制并逐渐增强至8 h采样结束。
  • 相对最大清除率变化:依非韦伦+59.1%、利福平+46.7%、口服伏立康唑-70.6%、静脉伏立康唑-61.1%。

临床怎么用

  • 可依据 perpetrator 起效时间设计CYP3A药物相互作用研究的采样时间点。
  • 短期联合不同 perpetrator 时,可参考已表征的时间过程界定预期无相关相互作用的联合间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytochrome P450 (CYP) 3A contributes to the metabolism of many approved drugs. CYP3A perpetrator drugs can profoundly alter the exposure of CYP3A substrates. However, effects of such drug-drug interactions are usually reported as maximum effects rather than studied as time-dependent processes. Identification of the time course of CYP3A modulation can provide insight into when significant changes to CYP3A activity occurs, help better design drug-drug interaction studies, and manage drug-drug interactions in clinical practice. OBJECTIVE: We aimed to quantify the time course and extent of the in vivo modulation of different CYP3A perpetrator drugs on hepatic CYP3A activity and distinguish different modulatory mechanisms by their time of onset, using pharmacologically inactive intravenous microgram doses of the CYP3A-specific substrate midazolam, as a marker of CYP3A activity. METHODS: Twenty-four healthy individuals received an intravenous midazolam bolus followed by a continuous infusion for 10 or 36 h. Individuals were randomized into four arms: within each arm, two individuals served as a placebo control and, 2 h after start of the midazolam infusion, four individuals received the CYP3A perpetrator drug: voriconazole (inhibitor, orally or intravenously), rifampicin (inducer, orally), or efavirenz (activator, orally). After midazolam bolus administration, blood samples were taken every hour (rifampicin arm) or every 15 min (remaining study arms) until the end of midazolam infusion. A total of 1858 concentrations were equally divided between midazolam and its metabolite, 1'-hydroxymidazolam. A nonlinear mixed-effects population pharmacokinetic model of both compounds was developed using NONMEM®. CYP3A activity modulation was quantified over time, as the relative change of midazolam clearance encountered by the perpetrator drug, compared to the corresponding clearance value in the placebo arm. RESULTS: Time course of CYP3A modulation and magnitude of maximum effect were identified for each perpetrator drug. While efavirenz CYP3A activation was relatively fast and short, reaching a maximum after approximately 2-3 h, the induction effect of rifampicin could only be observed after 22 h, with a maximum after approximately 28-30 h followed by a steep drop to almost baseline within 1-2 h. In contrast, the inhibitory impact of both oral and intravenous voriconazole was prolonged with a steady inhibition of CYP3A activity followed by a gradual increase in the inhibitory effect until the end of sampling at 8 h. Relative maximum clearance changes were +59.1%, +46.7%, -70.6%, and -61.1% for efavirenz, rifampicin, oral voriconazole, and intravenous voriconazole, respectively. CONCLUSIONS: We could distinguish between different mechanisms of CYP3A modulation by the time of onset. Identification of the time at which clearance significantly changes, per perpetrator drug, can guide the design of an optimal sampling schedule for future drug-drug interaction studies. The impact of a short-term combination of different perpetrator drugs on the paradigm CYP3A substrate midazolam was characterized and can define combination intervals in which no relevant interaction is to be expected. CLINICAL TRIAL REGISTRATION: The trial was registered at the European Union Drug Regulating Authorities for Clinical Trials (EudraCT-No. 2013-004869-14).

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Nassar YM, Hohmann N, Michelet R, et al. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion. Clin Pharmacokinet. 2022. PMID: 36195807. doi:10.1007/s40262-022-01175-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。